Treatment of severe bronchial asthma

Mepolizumab/mepolizumab - a new way to treat severe bronchial asthma

An additional treatment option for severe eosinophilic bronchial asthma using a new generation of drugs - monoclonal antibodies - is now available. About five years ago, the leading US Food and Drug Administration (FDA) approved the use of mepolizumab (Nucala, GlaxoSmithKline) in the complex therapy of refractory eosinophilic bronchial asthma in patients of various ages, including children from 12 years of age.

Mepolizumab is a humanized monoclonal antibody whose main focus of action is blocking interleukin-5, a factor that stimulates the maturation and activity of eosinophils. As a result of three large clinical trials devoted to the study of the peculiarities of mepolizumab use in patients with refractory eosinophilic bronchial asthma, it was possible to confirm the efficacy and safety of this drug. According to the results obtained, patients taking mepolizumab had an almost 50% reduction in the frequency of hospitalizations for severe asthma exacerbations, a reduction in the dose of systemic glucocorticoids and better disease control.

The drug is intended for additional treatment of severe bronchial asthma and can be used in combination with other medicines. The recommended doses of mepolizumab (Nucala) are 100 mg once every four weeks. Mepolizumab is administered by subcutaneous injection, in the upper arm, thigh, or abdomen.

The drug is available in a monodose vial, as a dry powder. Before administration, dilution with sterile water for injection is required according to the instructions.

If you have any questions about purchasing the original drug mepolizumab, please contact MedicalExpert managers.